Author

C. Gaggioli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:statistical model· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

A. Mallavialle· 2 shared C. Rovera· 2 shared I. Berestjuk· 2 shared M. Deckert· 2 shared M. Lecacheur· 2 shared S. Diazzi· 2 shared S. Tartare-Deckert· 2 shared T. Passeron· 2 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Mallavialle

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Invasive dedifferentiated melanoma cells inhibit JAK1-STAT3-driven actomyosin contractility of human fibroblastic reticular cells of the lymph node

C. Rovera, I. Berestjuk, M. Lecacheur, S. Diazzi, A. Mallavialle, J. Albrengues, C. Gaggioli, C. C. Girard, T. Passeron, M. Deckert, S. Tartare-Deckert, V. Prod'homme

The paper shows that dedifferentiated melanoma cells inhibit FRC contractility via JAK1-STAT3 and YAP pathways, reducing actomyosin forces and promoting LN remodeling.

bioRxiv · Mar 25, 2021 · PreprintCancer Biology

Targeting DDR1 and DDR2 overcomes matrix-mediated melanoma cell adaptation to BRAF-targeted therapy

S. Tartare-Deckert, I. Berestjuk, M. Lecacheur, S. Diazzi, C. Rovera, V. Prod'homme, A. Mallavialle, F. Larbret, S. Pisano, S. Audebert, T. Passeron, C. Gaggioli, C. Girard, M. Deckert

This study shows that targeting DDR1 and DDR2 overcomes matrix-mediated resistance to BRAF inhibitors in melanoma by disrupting ECM-driven survival pathways.

bioRxiv · Nov 28, 2019 · PreprintCancer Biology